Eligible health centers purchased $81.4 billion in discounted drugs under the federal 340B program in 2024, an increase of 23% from the previous year as

An FDA staff analysis of the safety of pediatric Covid-19 shots has been finalized and sent to the agency’s vaccine and biologics head Vinay Prasad.

As part of a batch of recommendations issued Friday, the European Medicines Agency’s human medicines committee (CHMP) recommended rejecting Anavex’s Alzheimer’s disease drug, issuing a

Roche and BioNTech stole the show at this year’s San Antonio Breast Cancer Symposium. The Swiss drugmaker unveiled Phase 3 data for its oral SERD

Another TIGIT program has failed in the clinic, this time in a Phase 3 study. Arcus and Gilead said on Friday that their anti-TIGIT antibody